NAT2 and colorectal carcinoma: Analyses of these two cohorts revealed five different NAT2 genotypes in heterozygous patients losing wild-type NAT2 in their tumors (Table 1) and motivated further understanding on whether CRC patients with the NAT2*4/5B or *4/7B haplotypes are also eligible for LOH-based therapy.